Work at Genecode AS has led to the identification of sulfonamide or sulfone compounds acting as GFRα1-RET receptor complex activators potentially useful for the treatment of neurological disorders.
Hanmi Pharmaceutical Co Ltd. has synthesized new heterobicyclic compounds acting as transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors and reported to be useful for the treatment of cancer.
Semmelweis University and University of Debrecen have jointly identified isochroman compounds reported to be useful for the treatment of bacterial infections.
Work at Ensem Therapeutics Inc. has led to the discovery of anilino-pyrazole derivatives acting as cannabinoid CB2 receptor agonists. As such, they are reported to be useful for the treatment of anxiety disorders, autoimmune disease, depression, neurodegeneration, neuroinflammation, osteoarthritis, chronic pain and substance abuse and dependence, among others.
Compounds acting as histone acetyltransferase KAT6A (MOZ; MYST-3) and KAT7 (HBO-1; MYST-2) inhibitors are reported in an Ideaya Biosciences Inc. patent as potentially useful for the treatment of cancer.
Deciphera Pharmaceuticals LLC has described new dual serine/threonine-protein kinase B-Raf (BRAF) and/or RAF proto-oncogene serine/threonine-protein kinase (RAF1; c-Raf) and microtubule destabilizers (tubulin polymerization inhibitors) potentially useful for the treatment of cancer.
Gasherbrum Bio Inc. has patented new heterocyclic glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of type 2 diabetes, among others.
AC Immune SA has synthesized new heterocyclic modulators acting as NLRP3 inflammasome inhibitors. As such, they are reported to be potentially useful for the treatment of asthma, atherosclerosis, obesity, gout, cryopyrin-associated periodic syndromes, nonalcoholic fatty liver disease (NAFLD), Parkinson’s and Alzheimer’s disease, among others.
RSS